Navrogen is a Cheyney, Pa.-based preclinical biotechnology company focused on discovering tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to cancer therapies. The company employs proprietary screening and engineering technologies and diagnostic assays to identify patients whose tumors produce HIO factors. Its pipeline includes a lead HIO-refractory anti-mesothelin antibody drug conjugate, NAV-001, and NK cell activator platforms targeting HIO-suppressed cancers and immune-mediated diseases. Navrogen’s mission is to develop first-in-class agents that overcome the immunosuppressive effects of HIO factors and to advise physicians on therapeutic options via diagnostics. The company is led by CEO Nicholas Nicolaides, Ph.D., and intends to advance its HIO discovery platform and preclinical therapeutic programs with the newly raised capital. Financially, Navrogen completed a $3.0M equity financing to fund these activities. Navrogen is a Philadelphia-based biotechnology company focused on discovering tumor-produced Humoral Immuno-Oncology (HIO) factors associated with cancer prognosis and response to immune-mediated therapies. Its core approach centers on an HIO discovery platform and a preclinical therapeutic pipeline targeting specific HIO-factors. The company’s stated mission is to develop diagnostic assays to identify patients whose tumors produce HIO-factors to advise physicians on therapeutic options. It also aims to develop agents that can overcome the immunosuppressive effects of specific HIO-factors. Navrogen is led by CEO Nicholas Nicolaides, Ph.D., and CSO Luigi Grasso, Ph.D. Following the financing, the company will use the funds to support operations, its HIO discovery platform, and preclinical pipeline activities.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2021